|
| Press Releases |
|
 |
|
| Tuesday, December 1, 2020 |
|
|
BioVaxys Provides Viral Vaccine Platform Program Update |
| BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) ("BioVaxys" or "the Company") is pleased to announce that it has received further data from its successfully completed murine model study demonstrating that immunizing mice with two doses of BVX-0320, its COVID-19 vaccine candidate, induced high levels of antibodies against the S1 fragment of the SARS-CoV-2 spike protein associated with inhibition of the binding of the virus to cells of the respiratory tract. more info >> |
|
| Monday, November 30, 2020 |
|
|
BioVaxys Provides Viral Vaccine Platform Program Update |
| BioVaxys Technology Corp. (CSE: BIOV) is pleased to announce that it has received further data from its successfully completed murine model study demonstrating that immunizing mice with two doses of BVX-0320, its COVID-19 vaccine candidate, induced high levels of antibodies against the S1 fragment of the SARS-CoV-2 spike protein associated with inhibition of the binding of the virus to cells of the respiratory tract. more info >> |
|
| Wednesday, November 11, 2020 |
|
|
BioVaxys Announces 96.4 Percent Positive Antibody Immune Response Results from an In Vivo Murine Model Study of Its SARS-CoV-2 Vaccine |
| BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) ("BioVaxys") is pleased to announce that results from its preclinical animal study (also known as the "murine model study") of BVX-0320, its Covid-19 vaccine candidate, show that the vaccine elicits a positive immune response against the SARS-CoV-2 s-spike protein. more info >> |
|
| Monday, November 2, 2020 |
|
|
BioVaxys Files Patent Application for Novel COVID-19 Diagnostic for T-Cell Immunity |
| BioVaxys Technology Corp. (CSE: BIOV) ("BioVaxys" or "the Company"), a world leader in haptenized protein vaccine research and development, announced today that it has filed a Provisional Patent Application with the U.S. Patent and Trademark Office entitled METHOD AND KIT FOR DETECTION OF CELL MEDIATED IMMUNE RESPONSE related to the potential development of a diagnostic for evaluating the presence or absence of a T-cell immune response to SARS-CoV-2, the virus that causes COVID-19. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
Supercomputer Fugaku retains first place worldwide in Graph500 rankings
Jun 10, 2025 19:47 JST
|
|
|
New HKTDC Chairman Frederick Ma keen to promote Hong Kong as best partner for global enterprises
Jun 10, 2025 17:31 HKT/SGT
|
|
|
ダイムラートラック、三菱ふそう、日野、トヨタ、三菱ふそうと日野の統合に関する最終合意を締結
Jun 10, 2025 16:30: JST
|
|
|
聯想控股副總裁于浩：在技術變革中錨定「長期主義」
Jun 10, 2025 15:37 HKT/SGT
|
|
|
联想控股副总裁于浩：在技术变革中锚定"长期主义"
Jun 10, 2025 15:28 HKT/SGT
|
|
|
Ai sẽ là người đầu tiên ghi danh vào lịch sử với tư cách là Nhà Vô Địch Thế Giới đầu tiên?!
Jun 10, 2025 14:00 HKT/SGT
|
|
|
Siapakah yang akan mengukir nama dalam sejarah sebagai "Juara Dunia Pertama"!
Jun 10, 2025 14:00 HKT/SGT
|
|
|
Siapakah yang akan mengukir namanya dalam sejarah sebagai “Juara Dunia Pertama”!
Jun 10, 2025 14:00 HKT/SGT
|
|
|
誰將成為名留青史的「初代世界冠軍」！
Jun 10, 2025 14:00 HKT/SGT
|
|
|
UK MOD Signs Protector Support Contract with GA-ASI
Jun 10, 2025 06:00 HKT/SGT
|
|
|
SRKay Consulting Group Releases Research Report: 'From Legal Frameworks to Successful Operations'--A Strategic Playbook for India Market Entry
Jun 9, 2025 17:00 HKT/SGT
|
|
|
Everest Medicines Presents Positive Results from Phase 1b/2a Clinical Trial of EVER001 for Primary Membranous Nephropathy at ERA 2025
Jun 9, 2025 12:52 HKT/SGT
|
|
|
雲頂新耀EVER001亮相ERA 2025 探索原發性膜性腎病治療新路徑
Jun 9, 2025 12:47 HKT/SGT
|
|
|
云顶新耀EVER001亮相ERA 2025 探索原发性膜性肾病治疗新路径
Jun 9, 2025 12:35 HKT/SGT
|
|
|
光大控股成功發行30億元人民幣熊貓中期票據
Jun 9, 2025 10:07 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
